Overview

CD40 Agonist and PD-1 Inhibitor in HNSCC

Status:
Not yet recruiting

Trial end date:
2028-03-01

Target enrollment:

Participant gender:

Summary

Prospective, open-label, phase 1 study of CD40 agonist (LVGN7409) and PD-1 inhibition (LVGN3616) in patients with resectable Human Papillomavirus (HPV)-negative mucosal head/neck squamous cell carcinoma (HNSCC). This protocol proposes to study the safety and immunological effects of LVGN7409, a CD40 agonistic antibody, when administered in combination with PD-1 inhibition prior to surgical resection.

Phase:

Phase 1

Details

Lead Sponsor:

University of Pennsylvania

Treatments:

Immune Checkpoint Inhibitors